Original from: 360dx

Myriad Genetics announced Tuesday that GlaxoSmithKline is sponsoring a program to boost access to homologous recombination deficiency (HRD) diagnostic testing for high-grade serous ovarian cancer (HGSOC) patients in nine countries via Myriad's MyChoice HRD Plus and MyChoice CDx Plus tests.

Under the terms of the agreement, the financial details of which were not disclosed, GSK will provide financial support for the testing program, which is taking place in Argentina, Brazil, Chile, Colombia, Egypt, the Netherlands, Saudia Arabia, Singapore, and the United Arab Emirates.

"Our collaboration with GSK is an important step forward in providing critical genetic insights that can help clinicians guide more personalized ovarian cancer treatment decisions," Patrick Burke, executive VP of strategy and innovation at Myriad, said in a statement. "In the pursuit of advancing healthcare equity, Myriad is committed to extending the reach of our diagnostic solutions, like Myriad's MyChoice Tests into additional markets to support more targeted patient care based on their genomic profile."

Earlier this year, Myriad teamed up with Qiagen to develop globally distributable kit-based HRD tests. These kits combine Qiagen's QiaSeq xHYB technology and Qiagen Digital Insight (QDI) informatics solution with Myriad's MyChoice CDx biomarkers.

Myriad reached a similar agreement with Illumina last year.

Source: Myriad, GSK Collaborate on International Ovarian Cancer Testing Program